Cardiomedex will be presenting a new HFpEF hamster model at the 37th Annual Meeting of the ISHR in Porto, Portugal from 10th to 13th of July2023.
This unique preclinical model will be presented during the July 10thposter session (poster #PO55) from 16:30-18:00 by Dr.Caroline Dubroca, Director of Research Development and Dr. Rana Assaly, Director of Scientific and Business Development at Cardiomedex.
This model showssevere heart failure with preserved ejection fraction (HFpEF) related to evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis and developsalterations in kidney function as characterized by our subsidiary company Physiognex. This preclinical model represents a unique opportunity to evaluate the efficacy of drugs targeting HFpEF
Reach out to Caroline Dubrocaor Rana Assaly during the ISHR meeting to learn how Cardiomedexanimal models and CRO services will drive your preclinical drug development to success.
Otherwise, contact us online to set-up an appointment with Dr. Assaly and/or discuss your drug development projects with us: